NCT05883748

HELIOS: Open-Label, Long-Term Extension Study to Investigate the Safety, Tolerability, and Efficacy of DISC-1459 (Bitopertin) in Participants With EPP or XLP

ENROLLING_BY_INVITATIONPHASE2, PHASE3INTERVENTIONAL

Trial Details

Start: 2023-08-31Est. Completion: 2028-06

Enrollment target: 230 participants

Locations

University of Alabama Hospital, Birmingham, Alabama, United States
University of California San Francisco, San Francisco, California, United States
University of Miami Miller School of Medicine, Miami, Florida, United States
Massachusetts General Hospital, Boston, Massachusetts, United States
MetroBoston Clinical Partners, Boston, Massachusetts, United States
Mount Sinai Hospital, New York, New York, United States
Atrium Health Wake Forest Baptist, Winston-Salem, North Carolina, United States
Remington-Davis Clinical Research, Columbus, Ohio, United States
Einstein Medical Center, Philadelphia, Pennsylvania, United States
University of Texas, Galveston, Texas, United States
Fred Hutchinson Cancer Center, Seattle, Washington, United States
Royal Prince Alfred Hospital, Camperdown, New South Wales, Australia
The Royal Melbourne Hospital, Parkville, Victoria, Australia
UZ Leuven, Leuven, Belgium
CHU de Nantes - Hôtel Dieu, Service de dermatologie, Nantes, France, France
Centre d'Investigation Clinique (CIC) Hôpital Bichat - Claude-Bernard, Paris, France, France

Erythropoietic Protoporphyria

The purpose of this study is to evaluate the concentration of afamelanotide in serum after the administration of afamela…

Leuven, BelgiumCompleted Oct 28, 2024

Erythropoietic Protoporphyria (EPP)X-Linked Protoporphyria (XLP)

The goal of this expanded access program is to provide bitopertin to patients with EPP and XLP who have no satisfactory …

Miami, United States

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.